Loading...
Introducing a specialist drug Kardex can significantly change prescribing practices for VTE in cancer patients
Coleman, N Young, R Greally, M O Riordan, L Breathnach, O Grogan, L
Coleman, N
Young, R
Greally, M
O Riordan, L
Breathnach, O
Grogan, L
Advisors
Editors
Other Contributors
Departments
Date
2014-06
Date Submitted
Keywords
CANCER
PRESCRIBING
PRESCRIBING
Other Subjects
Subject Mesh
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
Letter
Adobe PDF, 4.18 KB
Alternative Titles
Publisher
Abstract
We read with interest the results of the ENDORSE Study 1 . This study clearly demonstrated a high prevalence of risk for venous thromboembolism (VTE) and a low rate of prophylaxis use, particularly in medical patients. Of those at-risk medical and surgical patients with no contraindication to VTE prophylaxis, overall 57% received recommended VTE prophylaxis, with 64% surgical and 47% medical patients, receiving the recommended prophylaxis, respectively. We note that with regard to risk factors present prior to admission, active malignancy was an issue in only 6.7% (n=19) of the patients included in the study, and as inpatients only 2 patients (0.7%) underwent cancer therapy. As such, cancer patients are perhaps underrepresented in this cohort. Cancer is a well-known risk factor for the development of VTE, and VTE is a common and life-threatening condition in cancer patients, resulting in a shorter life expectancy than either cancer patients without VTE or noncancer patients with VTE 2,3 . Effective thromboprophylaxis reduces the risk for VTE and improves outcomes.
Language
en